Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,110
  • Shares Outstanding, K 3,001
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,510 K
  • EBIT $ 3 M
  • EBITDA $ 3 M
  • 60-Month Beta -0.29
  • Price/Sales 0.69
  • Price/Cash Flow N/A
  • Price/Book 0.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 1
  • High Estimate -0.74
  • Low Estimate -0.74
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +5.06%
on 11/15/24
4.15 -20.00%
on 10/28/24
-0.32 (-8.79%)
since 10/25/24
3-Month
3.08 +7.79%
on 10/14/24
4.15 -20.00%
on 10/28/24
-0.45 (-11.94%)
since 08/23/24
52-Week
3.00 +10.67%
on 08/13/24
8.98 -63.04%
on 02/01/24
-1.63 (-32.93%)
since 11/24/23

Most Recent Stories

More News
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Encinitas, California--(Newsfile Corp. - August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Encinitas, California--(Newsfile Corp. - July 30, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the European...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer,...

KPRX : 3.32 (-1.45%)
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Ken Gayron to Step Down as a Member of the Company's BoardEncinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced...

KPRX : 3.32 (-1.45%)
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to...

KPRX : 3.32 (-1.45%)
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be...

KPRX : 3.32 (-1.45%)

Business Summary

Kiora Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company. It involved in developing and commercializing products for treating ophthalmic diseases. The company's product pipeline includes KIO-301, KIO-101 and KIO-201. Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 3.48
2nd Resistance Point 3.45
1st Resistance Point 3.38
Last Price 3.32
1st Support Level 3.28
2nd Support Level 3.25
3rd Support Level 3.18

See More

52-Week High 8.98
Fibonacci 61.8% 6.70
Fibonacci 50% 5.99
Fibonacci 38.2% 5.29
Last Price 3.32
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar